ARWR: Arrowhead Pharmaceuticals Company Short-Term Debt

Symbol and logo of brand Arrowhead Corp (ARWR)

The evolution of short-term debt load demonstrates the success of Arrowhead Pharmaceuticals (ARWR) in the therapy of cardiovascular and hepatic pathologies, where the value of 0.00 records this metric. Arrowhead Pharmaceuticals (ARWR) is implementing energy-efficient laboratories to control toxic emissions during drug synthesis. The use of the innovative TRiM delivery system creates a robust technological barrier, protecting the biotech startup from competitor pressure in the patent race.

ARWR (Arrowhead Pharma) Company Short-Term Debts history from 07/04/2022 to 10/31/2026

Arrowhead Corp - analytical breakdowns and key metrics (ARWR)

- current quotes and average value forecast:
Price Chart Arrowhead Pharmaceuticals, Inc.|ARWR - Fair Value Consensus
- market capitalization information:
Market Value Arrowhead Pharmaceuticals, Inc.|ARWR - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Arrowhead Pharmaceuticals|ARWR - Book Capitalization|Market Cap to Net Assets Ratio arrowheadpharma.com|ARWR - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Arrowhead Pharmaceuticals|ARWR - Long-Term Debt to Equity|Short-Term Debt to Capital Arrowhead Pharmaceuticals|ARWR - Company Total Debt Obligations|Debt to Book Value Arrowhead Pharmaceuticals, Inc.|ARWR - Company Long-Term Debt|Company Short-Term Debts Arrowhead Pharmaceuticals|Quick Liquidity arrowheadpharma.com
- net income and valuation multiples indicators:
ARWR - Final Profit
Fundamental company analysis:Arrowhead Pharmaceuticals, Inc. - ARWR
Mass-produced product of Arrowhead Corp

This indicator assesses the issuer's liquidity via the volume of loans maturing within twelve months, allowing investors to decouple speculative volatility from fundamental business stability. By analyzing short-term balance sheet liabilities on GURU.Markets, an investor can determine how effectively Arrowhead Pharmaceuticals (ARWR) manages debt to fund the development of its RNA platform and scale partnerships for treating genetic pathologies.

Competitor analysis for Arrowhead Pharmaceuticals

MIRM - Company Short-Term Debt|Company Short-Term Loans and Borrowings DVAX (dynavax.com)|Arbutus (ABUS) - Company Short-Term Debt|Company Current Liabilities Inventiva Corp|GYRE (Gyre Therapeutics, Inc.) - Company Short-Term Debts|Company Short-Term Debts assemblybio.com|Company Current Liabilities GALT (Galectin Therapeutics)|GNFT (genfit.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debt DURECT DRRX|Aligos Therapeutics Inc. - Company Short-Term Debt|BioVie Pharma - Company Short-Term Debts|Short-Term Debt Volume Galmed Pharmaceuticals GLMD|NDRA (ENDRA Life Sciences Inc.) - Company Current Liabilities|HEPA (Hepion Pharmaceuticals, Inc.) - Company Short-Term Debt